This volume offers a balanced and comprehensive snapshot of the changing landscape for vaccine markets.

What are the economic barriers to bioterrirism vaccine development and distribution and the problem of liability exposure?

U.S. regulations are too cautious. Europe has adopted a more sensible approach.

Studies of vaccines have suffered from a focus on pricing and access, missing the crucial question of how they are developed and brought to market.

Members of an Institute of Medicine panel gathered at AEI on December 1 to discus the IOM's recently released report on the growing immunization problem.

The Global Fund is to be commended for its transparency, but it has failed to act on the information it has gleaned, and continues to allow its funds to be used by governmental distribution systems known to be corrupt.

A little fear goes a long way in fighting a pandemic.

The best way to confront a brand new flu bug is to avoid being swept by hysteria into serious policy mistakes.